Complement Factor P (Properdin)

$369.00

Purified human complement component Factor P.

Brand

Description

General Description
Complement factor P (properdin) is purified from normal human serum. Factor P is a 53,000 Dalton cationic protein that circulates in blood in the form of dimers, trimers
and tetramers. It binds rapidly to C3b on surfaces where complement has begun to activate. Properdin binds most avidly to C3b,Bb the alternative pathway C3/C5
convertase, but also binds to C3b < C3b,B < C3b,Bb. Its primary function is to stabilize the C3b,Bb complex allowing increased alternative pathway activation (Pang burn, M.K.,
(1988); Nolan, K.F. and Reid, K.B.M. (1993)). Properdin enhances formation of the alternative pathway C3 convertase by increasing binding of factor B to P,C3b complexes.
Thus, properdin is an accelerator (positive regulator) of complement activation. Properdin has recently been proposed to be able to also initiate activation of the
alternative pathway by binding to the target surface and initiating C3/C5 convertase formation (Kemper C. and Fourcade D.E. (2008)).

Physical Characteristics & Structure
The basic subunit of this protein is a 53,000 Dalton single chain molecule which is composed of six thrombospondin-like repeat (TSR) domains. These basic units are
linked at the ends (C-terminal to N-terminal) to form circular dimers, trimers, tetramers and perhaps higher forms in blood (Pang burn, M.K. (1989)). Electron microscopic
images (Smith, C.A. et al. (1984)) have clearly demonstrated these structures. Higher oligomers of properdin are formed upon freeze thaw and perhaps during complement
activation and were originally called “activated” properdin due to their enhanced ability to bind and activate complement. Properdin has a rare post-translational modification in
that its tryptophan residues are highly mannosylated (Hartmann, S. and Hofsteenge, J. (2000)). There is also a single N-linked glycosylation site near the C-terminal. These
contribute to a carbohydrate content estimated at 10%. Properdin is highly positively charged at neutral pH and has a pI greater than 9.5. It is one of the most positively
charged proteins in blood (Morley, B.J. and Walport, M.J. (2000)).
EC Number: EC 3.4.21.45

Function
Properdin binds most avidly to C3b,Bb the alternative pathway C3/C5 convertase, but also binds to C3b < C3b,B < C3b,Bb. Its primary function is to stabilize the C3b,Bb
complex allowing increased alternative pathway activation. Properdin enhances formation of the alternative pathway C3 convertase by increasing binding of factor B to
P,C3b complexes. Thus, properdin is an accelerator (positive regulator) of complement activation.

Assays
Assays depend on the ability of properdin to bind to clusters of C3b or to accelerate the activation of the alternative pathway. ELISA assays for protein may be
performed by coating plates with excess C3b (CompTech Cat# A114), binding properdin and detection with goat anti-Properdin (CompTech Cat# A239). Functional assays are
best performed using P-depleted serum (CompTech Cat# A339) and then neutrophils. In neutrophils it is stored in granules that release the properdin in response to C5a, FMLP,

IL8 and TNF-alpha.measuring the accelerated lysis of rabbit erythrocytes (CompTech Cat# B300) in the presence of

properdin (CompTech Cat# A139) and MgEGTA (CompTech Cat# B106). Lysis does  occur slowly in the absence of properdin so these assays must be timed assays to compare
the rates of lysis with and without properdin. Assays for “activated” properdin consist of incubating properdin in NHS for extended periods of time (30 to 60 min) and measuring
the residual C3 activity using C3-depleted serum (CompTech Cat# 313) and rabbit erythrocytes.

In vivo
Blood contains approximately 5 µg/mL properdin (Pang burn, M.K. (1989)). Properdin does not appear to be synthesized in the liver where most complement proteins
are synthesized. It is primarily made by monocytes, T-cells and

Regulation See In vivo above.

Specifications

Sizes Available:              100 µg
Concentration:                1.0 mg/mL (see Certificate of Analysis for actual concentration)
Form:                                Frozen liquid
Extinction Coeff.:           A280 nm = 1.78 at 1.0 mg/mL
Molecular weight:          53,000 Da (single chain)
Activity:                           >70% versus normal human serum standard
Purity:                              >90% by SDS-PAGE
Buffer:                              10 mM Sodium phosphate, 145 mM NaCl, pH 7.3
Preservative:                   None, 0.22 µm filtered.
Storage:                           -70o C or below. Avoid repeated freeze/thaw.
Source:                             Normal human serum (shown by certified tests to be negative for HBsAg, HTLV-I/II, STS, and for antibodies to HCV, HIV-1 and HIV-II).
Origin:                               Manufactured in the USA.

Safety and Handling

Precautions/Toxicity/Hazards
This protein is purified from human serum, therefore precautions appropriate for handling any blood-derived product must be used even though the source was shown by
certified tests to be negative for HBsAg, HTLV-I/II, STS, and for antibodies to HCV, HIV-1 and HIV-II.
Hazard Code: B   WGK Germany 3
MSDS available upon request.

Additional Information

Genetics
The gene for properdin is X-linked and resides on the short arm of the X chromosome between Xp11.3-Xp11.23. The gene is 6 kb is size with 10 exons.
Accession numbers: Human (X70872, X70872.1, X57748, M83652, S49355), Mouse (X12905), Guinea pig (S81116).

Deficiencies
Deficiencies are rare and can be the result of a total lack of properdin protein in blood or the presence of immunochemically detectable, but functionally inactive properdin.

Diseases
Deficiency of properdin results in recurrent fulminant meningococcal infections. Neis serial infections typically occur in young males, progress rapidly and can be fatal.

What Makes Us Unique?

GSA MEDICAL portfolio offers a comprehensive workflow for your lab needs with wide range of tools.

As of 2020, GSA MEDICAL INC. started providing premier Manufacturing services to the diagnostic industry. GSA MEDICAL can effectively analyze the feasibility of reagents for use in rapid immunoassays. This process offers a quick glance as to the potential a reagent or concept may have and can result in saving considerable time and money for GSAMEDICAL’s clients.

We provide strong personal support, technical competence, and experience to ensure customer expectations will be met or exceeded.

Shop Products